Success Metrics

Clinical Success Rate
96.3%

Based on 52 completed trials

Completion Rate
96%(52/54)
Active Trials
8(10%)
Results Posted
19%(10 trials)
Terminated
2(3%)

Phase Distribution

Ph phase_1
8
10%
Ph not_applicable
10
13%
Ph phase_3
9
11%
Ph phase_4
42
53%
Ph early_phase_1
1
1%
Ph phase_2
9
11%

Phase Distribution

9

Early Stage

9

Mid Stage

51

Late Stage

Phase Distribution79 total trials
Early Phase 1First-in-human
1(1.3%)
Phase 1Safety & dosage
8(10.1%)
Phase 2Efficacy & side effects
9(11.4%)
Phase 3Large-scale testing
9(11.4%)
Phase 4Post-market surveillance
42(53.2%)
N/ANon-phased studies
10(12.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.3%

52 of 54 finished

Non-Completion Rate

3.7%

2 ended early

Currently Active

8

trials recruiting

Total Trials

80

all time

Status Distribution
Active(10)
Completed(52)
Terminated(2)
Other(16)

Detailed Status

Completed52
unknown16
Recruiting8
Not yet recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
80
Active
8
Success Rate
96.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.3%)
Phase 18 (10.1%)
Phase 29 (11.4%)
Phase 39 (11.4%)
Phase 442 (53.2%)
N/A10 (12.7%)

Trials by Status

unknown1620%
not_yet_recruiting23%
completed5265%
recruiting810%
terminated23%

Recent Activity

Clinical Trials (80)

Showing 20 of 80 trialsScroll for more
NCT06402747Phase 4

Clopidogrel Versus Cilostazol on Vessels

Recruiting
NCT03109288Phase 1

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Recruiting
NCT06757764Phase 4

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Recruiting
NCT07238985Phase 1

Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease

Recruiting
NCT03855332Phase 2

Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

Completed
NCT07180472Phase 4

Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol

Not Yet Recruiting
NCT06492070Phase 2

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Recruiting
NCT05635370

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol

Completed
NCT04753970Phase 1

Retina is a Marker for Cerebrovascular Heath

Recruiting
NCT00823849Phase 4

Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

Completed
NCT06117436Phase 2

Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients

Completed
NCT03451591Phase 2

LACunar Intervention (LACI-2) Trial-2

Completed
NCT06612593Phase 2

Cilostazol in Parkinson's Disease

Not Yet Recruiting
NCT06522113Phase 4

Cilostazol and Aspirin in Stroke and TIA

Completed
NCT06530537Phase 3

Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds

Recruiting
NCT05594680Phase 3

Cilostazol and Methotrexate in Rheumatoid Arthritis

Recruiting
NCT05298696Phase 1

Efficacy of Cilostazol in Prevention of Peripheral Neuropathy

Completed
NCT05595993Not Applicable

Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache

Unknown
NCT02549898Not Applicable

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

Completed
NCT03581409Phase 4

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

Completed

Drug Details

Intervention Type
DRUG
Total Trials
80